XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, dose-escalation study (using 3 + 3 dose-limiting toxicity (DLT) criteria)
evaluating the safety and tolerability of XmAb18968, as well as establishing a recommended
phase II dose (RP2D) in subjects with T cell acute lymphoblastic leukemia (T-ALL) and T cell
lymphoblastic (lymphoma) T-LBL (Group A) and acute myeloid leukemia (AML) (Group B).